This phase 1 study assessed safety, tolerability, pharmacokinetics, and acceptability of cabotegravir in 47 HIV-negative adult Chinese men at low risk of acquiring HIV-1.
This Industry Update provides an overview of the some of the key events in the pharmaceutical world in December 2021.
An industry update: what’s new in the field of therapeutic delivery? Read More »
Osra Medical, an LGBTQ+ primary care Practice, a GGBA member and an NGLCC Certified LGBTBE Business Enterprise, announced they are now the first to provide injectable PrEP, Apretude, in San Francisco.
LGBTQ+ PHYSICIAN FIRST TO BRING APRETUDE (INJECTABLE PREP) TO SAN FRANCISCO Read More »
Lenacapavir, a long-acting HIV capsid inhibitor that could potentially be given every six months, continues to show good viral suppression, both in people starting antiretroviral therapy for the first time and in highly treatment-experienced people with multidrug-resistant virus, according to studies presented last week at the Conference on Retroviruses and Opportunistic Infections (CROI 2022).
Lenacapavir shows continued promise for first-line treatment and highly resistant HIV Read More »
Results From Trogarzo® IV Push Administration Study as presented at CROI
Results From Trogarzo® IV Push Administration Study Read More »
The Food and Drug Administration approved Apretude for use as what’s known as pre-exposure prophylaxis, or PrEP, against HIV on Dec. 20. The long-acting drug, which is meant to be injected every two months by a health care worker, joined two daily pills — Gilead Sciences’ Truvada and Descovy — that were approved as PrEP
1. Cabotegravir was shown to be superior to TDF-FTC in preventing HIV infection in women. 2. Both drugs were well tolerated and had similar adverse effects; however, there was a greater incidence of injection site reactions in the cabotegravir group.
This Viewpoint discusses the recent FDA approval of cabotegravir, the first injectable medication to help prevent HIV infection, and how its effectiveness may be complicated by the cost and complexity of the US health care system.
Long-acting Cabotegravir for HIV Prevention Issues of Access, Cost, and Equity Read More »
More than 50 members of Congress have signed a letter to the Centers for Disease Control and Prevention and the Centers for Medicare and Medicaid Service asking the agencies to make a new injectable treatment for HIV prevention free for patients.
Members of Congress ask CDC to cut cost of new HIV prevention drug Read More »
Oral cabotegravir + rilpivirine demonstrated efficacy in the majority of participants and an acceptable safety profile through 6 years of treatment, demonstrating its durability as maintenance therapy for HIV-1.
